TREATMENT OF HIGH LDL CHOLESTEROL
The FDA approved the novel PCSK9 inhibitor inclisiran, which uses silencing RNA technology to reduce liver production of PCSK9 protein by approximately 80%. Twice-yearly dosing is novel for lipid-lowering therapy; inclisiran enables new delivery strategies, including in-clinic administration.
Raal FJ et al; ORION-9 Investigators. N Engl J Med. [PMID: 32197277]
Ray KK et al; ORION-10 and ORION-11 Investigators. N Engl J Med. [PMID: 32187462]